Latest Asx Continuous Disclosure News

Resolution Minerals has clarified its compliance with ASX disclosure rules following a $2 million placement to Tribeca Investment Partners, confirming the transaction's material impact on its share price.

Vectus Biosystems has responded to an ASX price query following a dramatic spike in its share price and trading volume, denying any undisclosed information and confirming compliance with ASX rules.

Gladiator Resources has provided detailed clarifications to the ASX regarding its agreement with Apex USA Resources LLC for rare earth tenements in California, highlighting ongoing disputes and incomplete project milestones.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.

Bentley Capital Limited has addressed a sharp 70% rise in its share price and a spike in trading volume, attributing the movement to ongoing legal proceedings rather than undisclosed information.

4DS Memory Limited reveals a pivotal quarter marked by a strategic review, executive departures, and a contentious board nomination ahead of its AGM.

Auris Minerals has responded to an ASX price query following a sharp share price increase, confirming no undisclosed information is driving the move and outlining its ongoing exploration activities.

Domino’s Pizza Enterprises has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed acquisition talks despite market speculation.

PC Gold Ltd has clarified the timing, costs, and disclosure of its recent drilling and assay programs at the Spring Hill Project, affirming compliance with ASX rules ahead of its IPO.

AUB Group Limited has disclosed a conditional, non-binding proposal from an EQT affiliate to acquire the company at $45 per share, following unusual trading activity and media reports.

Clarity Pharmaceuticals has responded to ASX queries clarifying the timing and materiality of its SAR-bisFAP data presentation, denying the information was price sensitive despite a notable share price rise.

Cazaly Resources has addressed a sharp rise in its share price and trading volume, attributing the movement to strong gold and silver prices alongside a recent independent research report.